AC
ZYNE

Aristides Capital’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Aristides Capital’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-26,518
Closed -$160K – 268
2019
Q4 		$160K Buy
+26,518
New +$181K 0.12% 191

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Aristides Capital's ZYNE Position: Q1 2020 in Review

Aristides Capital sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2020, closing a stake of 26,518 shares — an estimated $160K sold.

Aristides Capital first reported a position in ZYNE in Q4 2019 and held it in 1 quarter. The position peaked at $160K in Q4 2019. 77 funds tracked by Wall St. Rank hold ZYNE as of Q1 2020.

  • Aristides Capital reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2020 after selling out during the quarter.
  • Aristides Capital sold 26,518 Zynerba Pharmaceuticals, Inc shares in Q1 2020, an estimated $160K.
  • Aristides Capital first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2019 and held it in 1 quarter.
  • Aristides Capital's Zynerba Pharmaceuticals, Inc position peaked at $160K in Q4 2019.
  • 77 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2020.

Based on Aristides Capital's 13F filing for Q1 2020, filed 15 May 2020.